Meta-analysisindependent cross-checkabstract checked I-SOD-126 standard review

Pooled studies: soda-kidney link uncertain

Sugar- and artificially-sweetened beverages and the risks of chronic kidney disease: a systematic review and dose-response meta-analysis.

Overview

Lo WC et al.. J Nephrol 2021 · PMID 33502726 · DOI 10.1007/s40620-020-00957-0

A meta-analysis found a non-significant 30% higher kidney-disease risk with high sugary-drink intake, with risk rising above seven drinks per week.

Does the study support the specific claim? Partly · Methodological quality: moderate

Original publication

Plain-language summary

Study explained simply
What did the researchers want to find out?

Pool studies on sweetened drinks and kidney disease.

How was the study done?

Meta-analysis.

How many people, animals or samples were studied?

About 25,000 people.

What was actually found?

Higher risk estimates, not statistically certain.

How large was the observed effect?

RR 1.30 (0.88-1.94).

What do the results mean in everyday life?

The link is possible but uncertain.

What are the study's limitations?

Few studies.

What does it say about Elawady's specific claim?

Neither proves nor disproves the claim.

Do the results apply to Germany and Europe?

Applicable.

What can explicitly not be concluded from this study?

Cannot prove causation.

Scientific in-depth review

1. Full reference

Authors
Lo WC et al.
Journal
J Nephrol
Year
2021
Identifier
PMID 33502726 DOI 10.1007/s40620-020-00957-0
Verification
verified – PubMed efetch 2026-10-26 + Crossref 2026-10-26
Retracted
no
Corrections
none
Extent checked
abstract only
Conflicts of interest and funding

Taiwanese hospital, university and ministry funding (PubMed record)

2. Research question

Is SSB or ASB consumption associated with CKD risk?

3. Study design and population

Study design
Meta-analysis – Systematic review and dose-response meta-analysis of observational studies (PubMed, Embase to February 2019)
Population

Adults

Country

International

Period

to 20 February 2019

Sample size

SSB: 6 studies (25,455); ASB: 3 studies (19,995)

Inclusion and exclusion criteria

Observational studies reporting RR for CKD or impaired renal function

4. Methods and endpoints

Exposure / intervention

SSB, ASB

Comparator

Low intake

Endpoints

CKD or impaired kidney function

Statistical methods

Random effects; dose-response

5. Actual results

Results

High vs low SSB: RR 1.30 (0.88-1.94); ASB: RR 1.40 (0.65-3.02); both non-significant. Dose-response: significantly increased CKD risk above seven servings per week (P<0.001).

Absolute risks

not reported

Authors' conclusion

Positive but non-significant association; more than seven servings per week should be avoided.

6. Strengths

  • Dose-response analysis

7. Weaknesses

  • Few, small studies
  • Imprecise
  • Mixed designs

8. Risk of bias

Orienting tool
AMSTAR 2
Type of assessment
simplified assessment (abstract only)
Full formal assessment
no
Overall risk of bias
some concerns
Rationale

Small evidence base.

9. Assessment of the statistical interpretation

Pooled CIs include 1; the dose-response signal is suggestive only.

10. Relevance to the specific claim

Mixed for C-SOD-09: direction positive, overall not statistically significant.

11. Independent contrary findings

Heo 2024 (I-SOD-125) significant.

12. Transferability to Germany and Europe

Applicable.

13. Overall methodological judgement

Weak pooled evidence predating UK Biobank analysis.

Multidimensional assessment
Multidimensional assessment
Authenticity of the sourceverified
Methodological qualitymoderate
Risk of biassome concerns
Precision of resultslow
Directnessdirect
Reproducibilitynot replicated
Consistency with the overall evidencemixed
Regional transferabilitymoderate
Adequacy of the interpretation (by the archive)not applicable

14. Open questions

Larger meta-analyses.

15. Linked fact checks